Search

The Spanish Rare Diseases Registries Research Network (SpainRDR) is a project aimed to build the National Rare Diseases Registry in Spain based on the input of two different methods: patient outcome research registries and population-based registries. The project has been approved within the IRDiRC framework and is co-funded by the Institute of Health Carlos III (ISCIII), the Health Departments of the Autonomous Communities (regions) and the Spanish Ministry of Health, Social Services and Equity (MSSSI) of Spain. The project addresses one of the main recommendations of the National Rare Diseases Strategy and also collaborates with some other RD registering actions like GRDR-NIH, RD-CONNECT and EPIRARE. With the unprecedented collaboration and support of medical societies, researcher networks, patient organizations, pharma industry and health policy makers, SpainRDR is running an effective and necessary way to develop knowledge and raise awareness of the rare diseases burden, which will contribute to design the provision of health and social services as well as the improvement of diagnosis, prognosis, treatment and quality life of patients and families affected by RD. The project is leading by the Institute of Rare Diseases research (IIER, ISCIII) and it is organised in six work packages: WP1 Coordination and Management, WP2 Registering activity related methods, WP3 Data analysis and outcomes research, WP4 Quality Assessment and ELSI issues, WP5 Dissemination and impact, and WP6 Patient registries. A Manual of Procedures including a quality assurance plan, common data elements, coding and classifications criteria, standard operating procedures, ELSI rules, statistical analysis methods and the official website network are actions already carried out or being finalized. Specific CDE have been also consolidated for those patient registries already implemented at the central RDR repository (alpha-1 antitrypsin deficiency, pulmonary histiocytosis, lymphangiomyomatosis, alveolar proteinosis, sarcoidosis, thraqueal stenosis, Sexual Developmental Disorders, Bullous Epidermolysis, ataxias and familiar spastic paraparesis). At the same time, some other patient registries' CDE´s are currently being developed, such as Congenital Suprarenal Hyperplasia and Bradykinin linked angioedema. We are preparing also CDEs for cystinosis and congenital anaemia. After the necessary pilot study developed during 2013, we are now collecting prevalence cases from 2012-2012 and the first preliminary results are already available using specific applications designed by SpainRDR.

Throughout the last few decades, different factors have been related to coronary stenosis which is clinically evidenced by coronary heart disease, the leading cause of death in developed countries. Different experimental models have contributed towards defining some of these factors, and to an understanding of the physiopathology of the atherosclerotic lesion. The genetic basis related to individual responses to the same event is currently being established. As endothelial injury reparative mechanisms are fundamental in atherosclerosis pathogeny, patients who experiment restenosis after undergoing revascularization procedures are useful human models in the study of these processes. We review from the literature the genetic factors related to thrombus formation, which may be associated with restenosis after percutaneous transluminal coronary angioplasty, in order to define the most suitable anticoagulant therapy for each patient. We refer to the recently characterized gene for the platelet receptors and its relationship with fibrinogenous, factor Xa, PAI-I, and the involvement of apolipoprotein (a) in the coagulation process.